The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study
Background. The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. Since the RAAS can induce and modulate pro-in...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/7/2315 |
id |
doaj-2c04eff6a90d477ba798521cc4d333fe |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Orianne Villard David Morquin Nicolas Molinari Isabelle Raingeard Nicolas Nagot Jean-Paul Cristol Boris Jung Camille Roubille Vincent Foulongne Pierre Fesler Sylvain Lamure Patrice Taourel Amadou Konate Alexandre Thibault Jacques Maria Alain Makinson Ivan Bertchansky Romaric Larcher Kada Klouche Vincent Le Moing Eric Renard Philippe Guilpain |
spellingShingle |
Orianne Villard David Morquin Nicolas Molinari Isabelle Raingeard Nicolas Nagot Jean-Paul Cristol Boris Jung Camille Roubille Vincent Foulongne Pierre Fesler Sylvain Lamure Patrice Taourel Amadou Konate Alexandre Thibault Jacques Maria Alain Makinson Ivan Bertchansky Romaric Larcher Kada Klouche Vincent Le Moing Eric Renard Philippe Guilpain The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study Journal of Clinical Medicine Covid-19 renin angiotensin aldosterone system inflammation endocrine severity |
author_facet |
Orianne Villard David Morquin Nicolas Molinari Isabelle Raingeard Nicolas Nagot Jean-Paul Cristol Boris Jung Camille Roubille Vincent Foulongne Pierre Fesler Sylvain Lamure Patrice Taourel Amadou Konate Alexandre Thibault Jacques Maria Alain Makinson Ivan Bertchansky Romaric Larcher Kada Klouche Vincent Le Moing Eric Renard Philippe Guilpain |
author_sort |
Orianne Villard |
title |
The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study |
title_short |
The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study |
title_full |
The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study |
title_fullStr |
The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study |
title_full_unstemmed |
The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study |
title_sort |
plasmatic aldosterone and c-reactive protein levels, and the severity of covid-19: the dyhor-19 study |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2020-07-01 |
description |
Background. The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. Since the RAAS can induce and modulate pro-inflammatory responses, it could play a key role in the pathophysiology of Covid-19. Thus, we aimed to determine the levels of plasma renin and aldosterone as indicators of RAAS activation in a series of consecutively admitted patients for Covid-19 in our clinic. Methods. Plasma renin and aldosterone levels were measured, among the miscellaneous investigations needed for Covid-19 management, early after admission in our clinic. Disease severity was assessed using a seven-category ordinal scale. Primary outcome of interest was the severity of patients’ clinical courses. Results. Forty-four patients were included. At inclusion, 12 patients had mild clinical status, 25 moderate clinical status and 7 severe clinical status. In univariate analyses, aldosterone and C-reactive protein (CRP) levels at inclusion were significantly higher in patients with severe clinical course as compared to those with mild or moderate course (<i>p</i> < 0.01 and <i>p </i>=<i> </i>0.03, respectively). In multivariate analyses, only aldosterone and CRP levels remained positively associated with severity. We also observed a positive significant correlation between aldosterone and CRP levels among patients with an aldosterone level greater than 102.5 pmol/L. Conclusions. Both plasmatic aldosterone and CRP levels at inclusion are associated with the clinical course of Covid-19. Our findings may open new perspectives in the understanding of the possible role of RAAS for Covid-19 outcome. |
topic |
Covid-19 renin angiotensin aldosterone system inflammation endocrine severity |
url |
https://www.mdpi.com/2077-0383/9/7/2315 |
work_keys_str_mv |
AT oriannevillard theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT davidmorquin theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT nicolasmolinari theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT isabelleraingeard theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT nicolasnagot theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT jeanpaulcristol theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT borisjung theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT camilleroubille theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT vincentfoulongne theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT pierrefesler theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT sylvainlamure theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT patricetaourel theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT amadoukonate theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT alexandrethibaultjacquesmaria theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT alainmakinson theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT ivanbertchansky theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT romariclarcher theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT kadaklouche theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT vincentlemoing theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT ericrenard theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT philippeguilpain theplasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT oriannevillard plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT davidmorquin plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT nicolasmolinari plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT isabelleraingeard plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT nicolasnagot plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT jeanpaulcristol plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT borisjung plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT camilleroubille plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT vincentfoulongne plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT pierrefesler plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT sylvainlamure plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT patricetaourel plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT amadoukonate plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT alexandrethibaultjacquesmaria plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT alainmakinson plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT ivanbertchansky plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT romariclarcher plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT kadaklouche plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT vincentlemoing plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT ericrenard plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study AT philippeguilpain plasmaticaldosteroneandcreactiveproteinlevelsandtheseverityofcovid19thedyhor19study |
_version_ |
1724671060447592448 |
spelling |
doaj-2c04eff6a90d477ba798521cc4d333fe2020-11-25T03:07:21ZengMDPI AGJournal of Clinical Medicine2077-03832020-07-0192315231510.3390/jcm9072315The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 StudyOrianne Villard0David Morquin1Nicolas Molinari2Isabelle Raingeard3Nicolas Nagot4Jean-Paul Cristol5Boris Jung6Camille Roubille7Vincent Foulongne8Pierre Fesler9Sylvain Lamure10Patrice Taourel11Amadou Konate12Alexandre Thibault Jacques Maria13Alain Makinson14Ivan Bertchansky15Romaric Larcher16Kada Klouche17Vincent Le Moing18Eric Renard19Philippe Guilpain20Montpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceDepartment of Infectious and Tropical Diseases, Montpellier University Hospital, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceDepartment of Endocrinology, Diabetes, Nutrition, and INSERM 1411 Clinical Investigation Centre, Montpellier University Hospital, INSERM, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceLaboratory of Virology, Montpellier University Hospital, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceDepartment of Internal Medicine—Multi-organ Diseases, local referral center for auto-immune diseases, Montpellier University Hospital, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceDepartment of Internal Medicine—Multi-organ Diseases, local referral center for auto-immune diseases, Montpellier University Hospital, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceMontpellier School of Medicine, University of Montpellier, 34000 Montpellier, FranceBackground. The new coronavirus SARS-CoV-2, responsible for the Covid-19 pandemic, uses the angiotensin converting enzyme type 2 (ACE2), a physiological inhibitor of the renin angiotensin aldosterone system (RAAS), as a cellular receptor to infect cells. Since the RAAS can induce and modulate pro-inflammatory responses, it could play a key role in the pathophysiology of Covid-19. Thus, we aimed to determine the levels of plasma renin and aldosterone as indicators of RAAS activation in a series of consecutively admitted patients for Covid-19 in our clinic. Methods. Plasma renin and aldosterone levels were measured, among the miscellaneous investigations needed for Covid-19 management, early after admission in our clinic. Disease severity was assessed using a seven-category ordinal scale. Primary outcome of interest was the severity of patients’ clinical courses. Results. Forty-four patients were included. At inclusion, 12 patients had mild clinical status, 25 moderate clinical status and 7 severe clinical status. In univariate analyses, aldosterone and C-reactive protein (CRP) levels at inclusion were significantly higher in patients with severe clinical course as compared to those with mild or moderate course (<i>p</i> < 0.01 and <i>p </i>=<i> </i>0.03, respectively). In multivariate analyses, only aldosterone and CRP levels remained positively associated with severity. We also observed a positive significant correlation between aldosterone and CRP levels among patients with an aldosterone level greater than 102.5 pmol/L. Conclusions. Both plasmatic aldosterone and CRP levels at inclusion are associated with the clinical course of Covid-19. Our findings may open new perspectives in the understanding of the possible role of RAAS for Covid-19 outcome.https://www.mdpi.com/2077-0383/9/7/2315Covid-19renin angiotensin aldosterone systeminflammationendocrineseverity |